Overview

Price chart · mood · technical indicators

ADCT

ADC Therapeutics SAstock Healthcare

Biotechnology

$3.50161.19%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$1.25$4.97

Current: $3.50

Idea: EMA

1Y Return

+103.6%

Sharpe 3Y

0.53

Market Comparison

vs Healthcare Sector & Biotechnology Industry

ADCT

+161.19%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-0.970.0% YoY

Profit margin-173.0%HEALTHCARE

Market cap$445.2MSmall cap

Wall Street coverage

$8.20median target· current $4.30 (+90.7%)6 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: —
PEG ratio: —
P/B: 3.42
P/S (TTM): 5.62
EV/EBITDA: -1.43

Profitability & growth

ROE (TTM): -706.0%
Operating margin: -121.1%
Revenue growth YoY: -9.5%
Dividend yield: —
Beta: 1.84

Last earnings

May 4, 2026 · Estimate $-0.20 · Reported $-0.21

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About ADC Therapeutics SA

Company profile

ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NYSE
Country: USA
Currency: USD

Company profile

HQ: BIOPOLE, EPALINGES, SWITZERLAND
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$445.2M

Shares outstanding$127.2M

52W high$4.98

52W low$1.25

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

ADCT

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

HC Wainwright & Co. Maintains ADC Therapeutics (ADCT) Buy Recommendation

Q2 EPS Estimate for ADC Therapeutics Decreased by Analyst

Analysts Have Made A Financial Statement On ADC Therapeutics SA's (NYSE:ADCT) First-Quarter Report

ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL (ADCT)

ADC Therapeutics SA 2026 Q1 - Results - Earnings Call Presentation (NYSE:ADCT) 2026-05-05

ADC Therapeutics S.A. (NYSE:ADCT) Q1 2026 Earnings Call Transcript

ADC Therapeutics to Host First Quarter 2026 Financial Results Co

ADC Therapeutics (NYSE: ADCT) posts Q1 2026 loss $33M, cash $231M

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics Releases Q1 2026 Financial Results

ADC Therapeutics S.A. Q1 2026 Earnings Call Summary

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates

ADC Therapeutics (NYSE: ADCT) narrows Q1 loss, sees cash runway into 2028

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

Two new hires at ADC Therapeutics receive 49,400 stock options

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Monday

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

About ADC Therapeutics SA

Classification

Company profile

ADCT

Market Comparison

ADCT Market Analysis

Overview

ADCT

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

HC Wainwright & Co. Maintains ADC Therapeutics (ADCT) Buy Recommendation

Q2 EPS Estimate for ADC Therapeutics Decreased by Analyst

Analysts Have Made A Financial Statement On ADC Therapeutics SA's (NYSE:ADCT) First-Quarter Report

ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL (ADCT)

ADC Therapeutics SA 2026 Q1 - Results - Earnings Call Presentation (NYSE:ADCT) 2026-05-05

ADC Therapeutics S.A. (NYSE:ADCT) Q1 2026 Earnings Call Transcript

ADC Therapeutics to Host First Quarter 2026 Financial Results Co

ADC Therapeutics (NYSE: ADCT) posts Q1 2026 loss $33M, cash $231M

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics Releases Q1 2026 Financial Results

ADC Therapeutics S.A. Q1 2026 Earnings Call Summary

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates

ADC Therapeutics (NYSE: ADCT) narrows Q1 loss, sees cash runway into 2028

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

Two new hires at ADC Therapeutics receive 49,400 stock options

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Monday

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

About ADC Therapeutics SA

Classification

Company profile

ADCT

Market Comparison